Abstract Number: 1240 • 2018 ACR/ARHP Annual Meeting
Foot Osteomyelitis in Inflammatory Rheumatic Diseases: A Retrospective Observational Study
Background/Purpose: Foot involvement is frequently pointed by patients with chronic inflammatory rheumatic diseases (IRD), such as rheumatoid arthritis (RA), spondyloarthritis (SpA) or psoriatic arthritis (PsA).…Abstract Number: 2915 • 2018 ACR/ARHP Annual Meeting
Can Passively-Collected Phone Behavior Determine Rheumatic Disease Activity?
Background/Purpose: Advances in reality mining combined with the pervasive use of smart phones have shown measurable changes in phone behavior due to changes in health.…Abstract Number: 1586 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs: A United States Subpopulation Analysis from Two Phase 3 Trials
Background/Purpose: Baricitinib (bari), an oral selective JAK1 and JAK2 inhibitor, has been shown to be safe and efficacious compared to placebo (PBO) in two Phase…Abstract Number: 1590 • 2016 ACR/ARHP Annual Meeting
Safety and Efficacy of Baricitinib in Elderly Patients with Moderate to Severe Rheumatoid Arthritis
Background/Purpose: Baricitinib (bari), an oral JAK1 and JAK2 inhibitor, is in development for patients (pts) with moderate to severe RA. Drug-related problems are common in…Abstract Number: 1591 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Switching from Adalimumab to Baricitinib: Phase 3 Data in Patients with Rheumatoid Arthritis
Background/Purpose: Baricitinib (bari) is an oral JAK1/JAK2 inhibitor under investigation for the treatment of patients (pts) with moderate to severe RA.1-2 In the 52-week Phase…Abstract Number: 1599 • 2016 ACR/ARHP Annual Meeting
Speed of Onset of Effect on Patient-Reported Outcomes Assessed through Daily Electronic Patient Diaries in the Baricitinib Phase 3 RA Clinical Program
Background/Purpose: Baricitinib (bari), an oral Janus kinase (JAK) 1/JAK2 selective inhibitor, has demonstrated clinical efficacy with a satisfactory safety profile when administered once daily in…Abstract Number: 2584 • 2016 ACR/ARHP Annual Meeting
Prevalence of Anemia Among Rheumatoid Arthritis Patients Treated with Conventional Disease-Modifying Antirheumatic Drugs
Background/Purpose: Anemia in rheumatoid arthritis (RA) patients (pts) has a prevalence of 16%-64% depending on population and severity of disease1,2,3 and is more common…Abstract Number: 3027 • 2016 ACR/ARHP Annual Meeting
Herpes Zoster in Patients with Moderate to Severe Rheumatoid Arthritis Treated with Baricitinib
Background/Purpose: Compared to the general population, RA patients (pts) have an increased risk of herpes zoster (HZ) due to their disease and various DMARD therapies…Abstract Number: 1584 • 2016 ACR/ARHP Annual Meeting
Bari-00074565
Background/Purpose: Baricitinib is an oral selective inhibitor of Janus kinases 1/2 and has demonstrated dose-dependent efficacy in moderate-to-severe RA patients who were DMARD-naïve or with…Abstract Number: 1585 • 2016 ACR/ARHP Annual Meeting
Previous Use of Conventional Disease-Modifying Antirheumatic Drugs and Response to Baricitinib
Background/Purpose: Baricitinib (BARI), an oral JAK1/JAK2 inhibitor, is in development for patients (pts) with moderate to severe RA.1,2 The purpose of this post hoc analysis…Abstract Number: 1250 • 2015 ACR/ARHP Annual Meeting
DNA Methylation and Its Relation to Immunological Phenotypes in Peripheral Blood: A Study of Anti-CCP Antibody Positivity from a Population-Based Pool
Background/Purpose: DNA methylation represents an important potential mediator of environmental influences on autoimmunity, including rheumatoid arthritis (RA). Genome-wide methylation in the context of clinical phenotypes…Abstract Number: 1463 • 2015 ACR/ARHP Annual Meeting
Anti-Cyclic Citrullinated Peptide Antibody Subclass Phenotypes in Polyarticular Juvenile Idiopathic Arthritis
Background/Purpose: Raised levels of Rheumatoid Factor (RhF) and antibodies to citrullinated proteins (ACPA), detected in the clinic using combinations of cyclic citrullinated peptides (CCP), are…Abstract Number: 1881 • 2014 ACR/ARHP Annual Meeting
Patients Who Fail Biologics Are More Likely to Have Concomitant Fibromyalgia
Background/Purpose: One area not assessed by studies to evaluate the efficacy of new medications in patients with inflammatory arthritis is whether the patient may have…Abstract Number: 2245 • 2013 ACR/ARHP Annual Meeting
Predictive Validity Of Low Disease Activity Using Patient Reported Measures On Long-Term Outcomes In Early Rheumatoid Arthritis- Results From Study Of New Onset Rheumatoid Arthritis and Ontario Best Practices Initiative
Background/Purpose: Patient reported outcome measures (PROM) are used in routine practice for assessment of disease activity. They have been shown to correlate well with other…Abstract Number: 461 • 2013 ACR/ARHP Annual Meeting
Higher TNFi Dosing Is Not Associated With More Serious Infectious Events (SIE), Elevated AST/ALT Or WBC<1.5 In The US Corrona Database
Higher TNFi Dosing Is Not Associated with More Serious Infectious Events (SIE), elevated AST/ALT or WBC 50 mg golim. q4wk for at least 3 months.Adverse…